Zimmer Biomet Holdings Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2022 / 08:00PM GMT
Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst

Good afternoon. I'm Robbie Marcus, the med tech analyst at JPMorgan. I'm very happy to host my next session with Zimmer Biomet. I have the CEO, Bryan Hanson; and the CFO, Suky Upadhyay. I think I was close there. Sorry, Suky. So we're going to diverge a little bit from the format we had for some of the other sessions. We're going to do 20 minutes of Q&A that allows Zimmer Biomet to highlight some of the really key topics today, and then we're going to move into 20 minutes of a little less formal Q&A. Please feel free to submit questions or e-mail me and I can do my best to get to all of them.

Questions and Answers:

Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst

But Bryan, Suky maybe to kick it off, Bryan, you've been at Zimmer Biomet for 4 years now. You've undergone this really big transformation process. Where do you sit now in the total process for Zimmer Biomet?

Bryan C. Hanson - Zimmer Biomet Holdings, Inc. -
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot